<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3118">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637867</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0761</org_study_id>
    <nct_id>NCT04637867</nct_id>
  </id_info>
  <brief_title>COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)</brief_title>
  <official_title>Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are still uncertainties about the existence of protective immunity and the duration of&#xD;
      protective antibodies in patients infected with SARS-CoV-2. Serological testing is an&#xD;
      appropriate tool for epidemiological investigations to assess the persistence of antibodies&#xD;
      over time. The nature of the immune response induced by this virus is also poorly understood.&#xD;
      This ancillary study aims at assessing the immunological characteristics of patients that&#xD;
      participated in the NOSO-COR study at Hospices Civils de Lyon six and twelve months after the&#xD;
      initial infectious episode.&#xD;
&#xD;
      Two visits will be scheduled at 6 and 12 months (Â± 1 month) after the initial SARS-CoV-2&#xD;
      infectious episode, Blood, saliva and nasopharyngeal samples will be collected for&#xD;
      seroprevalence and immunological investigation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence of SARS-CoV-2 antibodies in laboratory confirmed SARS-CoV-2 patients</measure>
    <time_frame>Month 6</time_frame>
    <description>To describe the immune response to SARS-CoV-2 infection by measuring the level of IgG and IgM in the blood of patients six months after laboratory-confirmed diagnosis of SARS-CoV-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprevalence of SARS-CoV-2 antibodies in laboratory confirmed SARS-CoV-2 patients</measure>
    <time_frame>Month 12</time_frame>
    <description>To describe the immune response to SARS-CoV-2 infection by measuring the level of IgG and IgM in the blood of patients 12 months after laboratory-confirmed diagnosis of SARS-CoV-2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infection Viral</condition>
  <arm_group>
    <arm_group_label>RT-PCR confirmed COVID-19 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>RT-PCR confirmed patients included in the NOSO-COR study are invited six and 12 months after the initial infection to provide blood (41.5mL in total), salivary and nasopharyngeal samples and to complete a questionnaire. Each visit is expected to take about one hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood, salivary and nasopharyngeal samples.</intervention_name>
    <description>Each visit M6 and M12&#xD;
Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)&#xD;
Salivary sample&#xD;
Nasopharyngeal sample</description>
    <arm_group_label>RT-PCR confirmed COVID-19 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        SARS-CoV-2 confirmed by RT-PCR&#xD;
&#xD;
          -  Adults &gt; 18 years&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
          -  Affiliated to the French health system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Hospitalized patients&#xD;
&#xD;
          -  Individuals subject to legal protection&#xD;
&#xD;
          -  Imprisoned individuals&#xD;
&#xD;
          -  Individuals who have expressed an opposition to participate, or who do not wish to&#xD;
             donate blood samples&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe VANHEMS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lyon, France, 69003</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe VANHEMS, MD</last_name>
    <phone>04 72 11 07 20</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.vanhems@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MITRA ELAHI, PhD</last_name>
    <phone>04 72 11 07 20</phone>
    <phone_ext>+33</phone_ext>
    <email>mitra.elahi@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe VANHEMS, MD</last_name>
      <phone>04 72 11 07 20</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.vanhems@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

